Attachment: Product Information: Linagliptin
... Ltd PM-2012-01168-3-5 Final 26 September 2013. This Product Information was approved at the time this AusPAR was published. ...
... Ltd PM-2012-01168-3-5 Final 26 September 2013. This Product Information was approved at the time this AusPAR was published. ...
COMPARACIÓN ENTRE PAQUIMETRÍA ÓPTICA Y ULTRASÓNICA
... Recruitment and Follow-up - Recruitment during one year period. - Patients who met inclusion criteria were enrolled after informed consent. - Autologous serum was obtained and prescribed 6 times a day for 1 month. - 3 months follow-up with monthly visits. - Parameters evaluated every visit: Best-cor ...
... Recruitment and Follow-up - Recruitment during one year period. - Patients who met inclusion criteria were enrolled after informed consent. - Autologous serum was obtained and prescribed 6 times a day for 1 month. - 3 months follow-up with monthly visits. - Parameters evaluated every visit: Best-cor ...
Document
... increased, and minimal observed toxicity allows for higher dosing in younger children (up to 5mg/kg/dose twice daily). Under-dosing must be avoided wherever possible due to low barrier development of HIV drug resistance. A reduced dose (150200mg/m2/dose once daily) is recommended for the first 2 wee ...
... increased, and minimal observed toxicity allows for higher dosing in younger children (up to 5mg/kg/dose twice daily). Under-dosing must be avoided wherever possible due to low barrier development of HIV drug resistance. A reduced dose (150200mg/m2/dose once daily) is recommended for the first 2 wee ...
Tussionex®
... over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of ...
... over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of ...
aclasta - Medsafe
... before initiating therapy with Aclasta (see Contraindications). Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve; thyroid surgery, parathyroid surgery, intestinal calcium malabsorption). Physicians should consider clinical monitoring for ...
... before initiating therapy with Aclasta (see Contraindications). Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve; thyroid surgery, parathyroid surgery, intestinal calcium malabsorption). Physicians should consider clinical monitoring for ...
Complications of Antiretroviral Therapy
... CRIXIVAN, are used concurrently with other HMG-CoA reductase inhibitors metabolized by the CYP3A4 pathway (eg, atorvastatin or rosuvastatin). The risk of myopathy including rhabdomyolysis may be increased when HIV protease inhibitors, including CRIXIVAN, are used in combination with these drugs Part ...
... CRIXIVAN, are used concurrently with other HMG-CoA reductase inhibitors metabolized by the CYP3A4 pathway (eg, atorvastatin or rosuvastatin). The risk of myopathy including rhabdomyolysis may be increased when HIV protease inhibitors, including CRIXIVAN, are used in combination with these drugs Part ...
DEPRESSION: MASTER
... treatment of anxiety disorders may increase anxiety in the short term • Use low doses and increase slowly ...
... treatment of anxiety disorders may increase anxiety in the short term • Use low doses and increase slowly ...
OVERVIEW OF THE ANTIDIABETIC AGENTS
... Shortest half-life (2-4 hours) as the parent drug but extended released formulation ("XL") also is available providing 24-hour action. It is extensively metabolized by the liver (90%); 10% excreted unchanged by the kidney. It is metabolized primarily by ring ω and ω-1 oxidations with cis-3-OH and tr ...
... Shortest half-life (2-4 hours) as the parent drug but extended released formulation ("XL") also is available providing 24-hour action. It is extensively metabolized by the liver (90%); 10% excreted unchanged by the kidney. It is metabolized primarily by ring ω and ω-1 oxidations with cis-3-OH and tr ...
Dabigatran (Pradaxa) Guidelines
... Note: All clotting times will be abnormal on dabigatran. We are not yet sure if our fibrinogen testing is reliable on the drug, it may be low, this is under investigation. ...
... Note: All clotting times will be abnormal on dabigatran. We are not yet sure if our fibrinogen testing is reliable on the drug, it may be low, this is under investigation. ...
Pharmacologic treatment of Parkinson disease:
... Entacapone should be given first because of the small risk that tolcapone can cause an elevation of liver enzymes. Consider adding an oral dopamine agonist such as pramipexole or ropinirole. Watch for dopaminergic toxicity such as visual hallucinations and confusion, and be prepared to lower the lev ...
... Entacapone should be given first because of the small risk that tolcapone can cause an elevation of liver enzymes. Consider adding an oral dopamine agonist such as pramipexole or ropinirole. Watch for dopaminergic toxicity such as visual hallucinations and confusion, and be prepared to lower the lev ...
Heart Listen - Men`s Health Network
... INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus. WARNINGS Liver Enzymes HMG-CoA reductase inhibitors, like some other lipidlowering therapies, have been ...
... INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus. WARNINGS Liver Enzymes HMG-CoA reductase inhibitors, like some other lipidlowering therapies, have been ...
Abstral sublingual tablet ENG SmPC
... (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 15-30 minutes of the first dose an increase in dose to the next highest tablet strength should be considered for the next episode of breakthrough pain (Refer to figure below). Dose escalation s ...
... (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 15-30 minutes of the first dose an increase in dose to the next highest tablet strength should be considered for the next episode of breakthrough pain (Refer to figure below). Dose escalation s ...
Ocular side effects of antitubercular drugs
... contribute to poor visual outcome. In the group over 60 years old, only 20% (1/5) experienced visual improvement; in the group less than 60 years old, 80% (4/5) had some visual recovery, the difference between these two age groups being statistically significant. The authors mention that they need m ...
... contribute to poor visual outcome. In the group over 60 years old, only 20% (1/5) experienced visual improvement; in the group less than 60 years old, 80% (4/5) had some visual recovery, the difference between these two age groups being statistically significant. The authors mention that they need m ...
Hypertension Management of the “Difficult Patient”
... Stenosis is considered >=50% luminal narrowing Clinically relevant (also called “critical”) stenosis is not well defined (50-70% by some pharmacologic studies vs. 80% by renal vein renin ...
... Stenosis is considered >=50% luminal narrowing Clinically relevant (also called “critical”) stenosis is not well defined (50-70% by some pharmacologic studies vs. 80% by renal vein renin ...
Overview of Vinca Alkaloids
... blocking of axonal transport that causes the damage Usually starts as symmetrical sensory impairment and paresthesias in extremities (“stocking-glove” sensations) Motor dysfunction, foot and wrist drop and paralysis can occur ...
... blocking of axonal transport that causes the damage Usually starts as symmetrical sensory impairment and paresthesias in extremities (“stocking-glove” sensations) Motor dysfunction, foot and wrist drop and paralysis can occur ...
5-7 days - FertilityCenter
... in the <36 years group (P < 0.025). The probability of conception after three treatment cycles was 0.402 overall, 0.481 for age <36 years and 0.252 for age 36 years. The probability of conception for male factor and idiopathic infertility patients was 0.469 and 0.411 respectively. An age effect was ...
... in the <36 years group (P < 0.025). The probability of conception after three treatment cycles was 0.402 overall, 0.481 for age <36 years and 0.252 for age 36 years. The probability of conception for male factor and idiopathic infertility patients was 0.469 and 0.411 respectively. An age effect was ...
full Prescribing Information
... about operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ/BELVIQ XR therapy does not affect them adversely [see Patient Counseling Information (17)]. ...
... about operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ/BELVIQ XR therapy does not affect them adversely [see Patient Counseling Information (17)]. ...
Anthelminthic drugs
... into the lung, where they die – only active against Schistosoma haematobium, but not eggs – abdominal pain – interactions with peripheral muscle relaxants and organophosphates have to be minded ...
... into the lung, where they die – only active against Schistosoma haematobium, but not eggs – abdominal pain – interactions with peripheral muscle relaxants and organophosphates have to be minded ...
ยา Pitavastatin กับการ Reverse โรคหลอดเลือดหัวใจตีบ Tertiary source
... baseline in LDL-C was -44% and -43% in the pitavastatin 4-mg and simvastatin 40-mg groups, respectively (adjusted mean treatment difference, 1.1%; 95% CI, -2.1% to 4.3%). Analysis of the PP population confirmed the FAS results (data not provided). There were no significant differences between the g ...
... baseline in LDL-C was -44% and -43% in the pitavastatin 4-mg and simvastatin 40-mg groups, respectively (adjusted mean treatment difference, 1.1%; 95% CI, -2.1% to 4.3%). Analysis of the PP population confirmed the FAS results (data not provided). There were no significant differences between the g ...
Proton Pump Inhibitors
... Unless otherwise specified, maintenance therapy, at the recommended daily maintenance dose (Tables 2 and 3), may be continued indefinitely based on patient need. Omeprazole treatment for EE and GERD in pediatric patients may continue indefinitely. PPI treatment duration in adults for H. pylori eradi ...
... Unless otherwise specified, maintenance therapy, at the recommended daily maintenance dose (Tables 2 and 3), may be continued indefinitely based on patient need. Omeprazole treatment for EE and GERD in pediatric patients may continue indefinitely. PPI treatment duration in adults for H. pylori eradi ...
ANTHELMINTIC DRUGS
... erratically (unpredictable) , absorption can be increased with fatty meal ...
... erratically (unpredictable) , absorption can be increased with fatty meal ...
Package Insert - Merck Animal Health
... with the absorption of quinolones resulting in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided. The dosage of theophylline should be reduced when used concu ...
... with the absorption of quinolones resulting in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided. The dosage of theophylline should be reduced when used concu ...
History of anticoagulant therapy
... • Less than 10% absorbed; relatively high rate of GI side effects • Crosses the placenta – do not use during pregnancy • Drug may degrade over time after exposure to air – must be kept in original packaging Unused tablets should be discarded after 90 days * Not FDA-approved indication ...
... • Less than 10% absorbed; relatively high rate of GI side effects • Crosses the placenta – do not use during pregnancy • Drug may degrade over time after exposure to air – must be kept in original packaging Unused tablets should be discarded after 90 days * Not FDA-approved indication ...
Product Information for Triptorelin Acetate
... DECAPEPTYL 100 micrograms/1 mL is contraindicated during pregnancy (see CONTRAINDICATIONS). Pregnancy must be excluded before initiation of fertilisation treatment. Nonhormonal methods of contraception should be employed during therapy until menses resume. If a patient becomes pregnant while receivi ...
... DECAPEPTYL 100 micrograms/1 mL is contraindicated during pregnancy (see CONTRAINDICATIONS). Pregnancy must be excluded before initiation of fertilisation treatment. Nonhormonal methods of contraception should be employed during therapy until menses resume. If a patient becomes pregnant while receivi ...
ADVERSE DRUG REACTIONS IN ADULTS LEADING TO EMERGENCY DEPARTMENT VISITS
... Age distribution of the patients in our study showed 60% were above the age of 50 years. As compared to a previous study, more than 14% 28.2% of elderly admissions were due to drugs 11-12. Elderly age group patients are at high risk of developing drug related adverse effects because of increased sen ...
... Age distribution of the patients in our study showed 60% were above the age of 50 years. As compared to a previous study, more than 14% 28.2% of elderly admissions were due to drugs 11-12. Elderly age group patients are at high risk of developing drug related adverse effects because of increased sen ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.